Search
Fospropofol
go.drugbank.com/drugs/DB06716ApprovedIllicitInvestigationalWithdrawnUnlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.
Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation. … [A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]
Categories: Agents to Treat Airway DiseaseButenafine
go.drugbank.com/drugs/DB01091ApprovedButenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. … In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.
Synonyms: N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine, (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamineDesogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigational[A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762] … [T521] Desogestrel is now produced semi-synthetically from naturally occurred plant steroids.[F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].
Mixtures: O - ZETTEVardenafil
go.drugbank.com/drugs/DB00862Approved[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis … Although other PDE5 inhibitors such as [sildenafil] and [tadalafil] have been associated with rare cases of acute liver injury, the use of vardenafil has not been linked to hepatotoxic effects.
Pirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigational[A251370] While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. … [A251365] The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.[A251165]
Categories: Analgesics, Non-NarcoticGefapixant
go.drugbank.com/drugs/DB15097Approvedor unexplained chronic cough (UCC) when no diagnosable cause for the cough can be determined. … [L48601] A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment
Selenious acid
go.drugbank.com/drugs/DB11127ApprovedSelenium (Se) has been demonstrated to prevent cancer in numerous animal models when administered selenium at levels exceeding the nutritional requirements. … The reports from such studies have heightened the interest in additional human selenium supplementation studies to validate the results in larger populations [L1918].
Mixtures: Addamel N, ADDAMEL NBevirimat
go.drugbank.com/drugs/DB06581InvestigationalIt is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos. … This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics.
Indium In-111 imciromab pentetate
go.drugbank.com/drugs/DB09339ApprovedWithdrawnIndium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.